Notable Earnings: Aecom Tech (ACM), Cancer Genetics (CGIX), (CRCM)

Aecom (ACM) shares are down $0.75 to $31.00 in pre-market trading Tuesday after the company reported its second quarter earnings results.

The provider of technical and management-support services reported non-GAAP earnings of $0.58 per share on revenues of $4.51 billion, up 140.7% from $1.87 billion a year ago. Analysts were expecting EPS of $0.53 on revenues of $4.43 billion. Q2 gross profit was $103.3 million, up 18.2% from $87.4 million a year earlier. The company’s net income for the period came in at $266,000.

“We delivered strong organic revenue growth and made substantial progress on our integration priorities,” said in a statement Michael S. Burke, AECOM’s chairman and CEO. “The solid results we delivered today reflect our global leadership position and the complementary skill sets we have integrated over time. We are on track with our vision to become the world’s premier fully integrated infrastructure services firm, and our addressable market opportunity has never been greater.”

“We generated strong free cash flow through the first half of the fiscal year,” added AECOM’s President and CFO Stephen M. Kadenacy. “This cash generation drove our debt reduction as we build on our track record of disciplined capital allocation.”

Liquidity: As of March 31, 2015, AECOM reported $613 million in total cash and cash equivalents vs. $4.87 billion in debt. The Los Angeles, California-based company generated free cash flow of $277 million.

For full-year 2015, ACM provided EPS guidance of $3.15 – $3.55 versus consensus of $2.88 per share.

Cancer Genetics, Inc. (CGIX) reported first quarter EPS of ($0.44) before the opening bell Tuesday, compared to the consensus estimate of ($0.54). Revenues increased 205.6% from last year to $4.37 million. Analysts expected revenues of $3.85 million. Q1/15 net income was a loss of $4.3 million, or ($0.44) per diluted share, which compares to a net income loss of $2.5 million, or ($0.27) per diluted share in the 2014 first quarter. Q1/15 gross profit was $1.2 million, an improvement of more than 28%, or $1.2 million, from 9.8% or $0.1 million over Q1/14.

“We continue to make strong progress in driving market adoption, revenue growth, and developing a unique, unrivaled portfolio of genomic capabilities in oncology,” stated Panna Sharma, CEO & President of Cancer Genetics, Inc. “We are pleased with the continued acceleration of our business and revenue with our biopharma partners, and in the rapid adoption of our NGS panels and genomic knowledge into active clinical trials.”

On valuation measures, Cancer Genetics Inc. shares, which currently have an average 3-month trading volume of 78K shares, trade at a P/E to growth ratio of (0.11). The median Wall Street price target on the name is $14.00 with a high target of $15.75.

Profitability-wise, CGIX has a t-12 profit and operating margin of (163.18%) and (188.34%), respectively. The $89.76 million market cap company reported $22.3 million in cash in its most recent quarter.

CGIX currently prints a one year loss of about 19% and a year-to-date return of around 37%.

The chart below shows where the equity has traded over the last 52 weeks., Inc. (CRCM) shares lost over 6% to $6.03 in pre-market trading after it reported fiscal-first quarter earnings.

The operator of an online service to help people find and manage family care handed in earnings of ($0.33) per share on revenue of $35.1 million, missing Wall Street estimates of ($0.31) per share on revenue of $34.19 million. First quarter net loss was $12 million, or ($0.38), as compared to a net loss of $15.5 million, or ($0.71) per share in the first quarter 2014.

“We are making excellent progress growing our business while achieving sales and marketing leverage and optimizing our products. We believe we are on track to meet our expectations of achieving overall adjusted EBITDA profitability by the end of fiscal 2016, driven by our US Matching and Payments businesses, which combined were breakeven on Operating Income and profitable on adjusted EBITDA in Q1 2015 for the second quarter in a row,” said in a press release Sheila Lirio Marcelo, Founder, Chairwoman, and CEO of

Looking forward, expects fiscal second-quarter 2015 revenue to range between $34 – $36 million, versus current expectations for $35.02 million.

Cash Position: Waltham, Massachusetts-based company ended the quarter with $62.7 million in cash and cash equivalents, compared to $71.8 million at Dec. 27, 2014.

Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.